Bowel cancer, also known as colorectal cancer, can affect any part of the colon or rectum; it may also be referred to as colon cancer or rectal cancer, depending on where the cancer is located.
Bowel cancer screening is for people who do not already have bowel cancer, symptoms of bowel cancer, or any reason to have a high risk of bowel cancer.
Patient-centred care is healthcare that is respectful of, and responsive to, the preferences, needs and values of patients and consumers.
Bowel Cancer Australia provides essential support services uniquely designed for bowel cancer patients via our confidential Helpline with specialist telehealth support, as well as a national Peer-to-Peer Support Network and Buddy Program.
Bowel Cancer Australia funds research that has the potential to improve survival and/or help build a path toward a cure and integrates published research into our awareness, advocacy, and support strategies.
Bowel Cancer Australia relies upon donations and the support of hard working and enthusiastic fundraisers across the country to continue our life saving work. We raise funds to continue our life-saving work and inspire others to do the same, so everyone affected by bowel cancer can live their best life.
In November 2024, Bowel Cancer Australia in collaboration with A/Prof Daniel Buchanan, Head of the Colorectal Oncogenomics Group, Department of Clinical Pathology and Centre for Cancer Research, University of Melbourne co-hosted a national, multidisciplinary Early-Onset Bowel Cancer Research Symposium.
The inaugural Symposium embraced the authentic patient voice and identified priorities and innovative research ideas focused on early-onset bowel cancer biology and aetiology, prevention and early detection, treatment, survivorship and recurrence.
Experts helped shape development of an Early-Onset Bowel Cancer Research Roadmap and Action Plan through shared knowledge and collaborative clinical and scientific efforts.
Bowel Cancer Australia is the trusted national voice in raising awareness of the rising rates of early-onset bowel cancer and through its #Never2Younhg Advocacy Agenda, seeks to improve care experiences and health outcomes for younger people through research advocacy into the causes of early-onset bowel cancer, that has the potential to improve survival and/or help build a path towards a cure.
A/Prof Buchanan is a NHMRC Emerging Leadership Investigator Fellow and a University of Melbourne Dame Kate Campbell Fellow. He leads a multi-disciplinary research program focused on understanding the causes of bowel cancer to inform precision prevention and early detection. The ANGELS and Genetics of Colonic Polyposis Studies use genomics to identify the aetiology of early-onset bowel cancer, and idiopathic polyposis cases that remain a significant clinical challenge.
Thank you, A/Prof Daniel Buchanan, Dr Celine Garrett, Dr Gaston Arnolda, Prof Ingrid Winship, Dr Jacob McCormick, Dr Kirsty Campbell, Dr Lisa Mielke, Dr Lochlan Fennell, Prof Mark Jenkins, Prof Mark Molloy, and Prof Michael Samuel for sharing your latest research, valuable insights, and collaborative intent. Special thanks to Nina Di Santo for sharing her lived experience.
Associate Professor Daniel Buchanan, University of Melbourne